Skip to main content

Advertisement

We’d like to understand how you use our websites in order to improve them. Register your interest.

Diagnostic, traitement et surveillance de l’hypogonadisme de survenue tardive chez l’homme: Recommandations officielles de l’International Society for the Study of the Aging Male (ISSAM) et commentaires

Investigation, treatment and monitoring of lateonset hypogonadism in males: the official guidelines of the International Society for the Study of the Aging Male (ISSAM), with comments

Resume

Les altérations hormonales de l’homme vieillissant représentent un sujet d’intérêt croissant, aux enjeux importants liés au développement attendu de cette population d’hommes âgés de plus de 50 ans.

Les préoccupations actuelles concernent essentiellement le déclin des androgènes chez l’homme vieillissant (androgen decline in the aging male: «ADAM»), ou déficit partiel en androgènes de l’homme vieillissant (partial androgen deficiency of the aging male: «PADAM»), communément appelée «andropause» en France. Si les connaissances au sujet du déficit androgénique de l’homme âgé ont progressé, elles sont encore incomplètes, parfois confuses, et certains points concernant le traitement androgénique substitutif restent controversés.

C’est pourquoi l’International Society for the Study of the Aging Male (ISSAM) a jugé opportun de faire le point sous la forme d’une série de recommandations pratiques et officielles concernant le diagnostic, le traitement et la surveillance de l’hypogonadisme de survenue tardive chez l’homme.

Le but de ce travail est de présenter ces recommandations internationales récentes, sous la forme de leur traduction française, et de les commenter.

Abstract

There is increasing interest in the subject of hormone changes in the aging male, which is likely to become particularly important with the expected growth in the population of men over 50.

The main concerns at present are androgen decline in the aging male (ADAM), or partial androgen deficiency of the aging male (PADAM), commonly known as the andropause. Although progress has been made in our knowledge of androgen deficiency in the aging male, it is still incomplete and sometimes confusing, and some aspects of androgen replacement therapy remain controversial.

The International Society for the Study of the Aging Male (ISSAM) therefore felt it was a good time to review the current situation by publishing a series of practical and official guidelines concerning the diagnosis, treatment and monitoring of late-onset hypogonadism in males.

The aim of this study is to present and discuss the French translation of these recent international guidelines.

References

  1. 1.

    ALEXANDER G.M., SWERDLOFF R.S., WANG C., DAVIDSON T., MCDONALD V., STEINER B.: Androgen-behavior correlations in hypogonadal men and eugonadal men. II. Cognitive abilities. Horm. Behav., 1998, 33: 85–94.

  2. 2.

    AMMUS S.S.: The role of androgens in the treatment of hematologic disorders. Adv. Intern. Med., 1989, 34: 191–208.

  3. 3.

    ARLT W., CALLIES F., VAN VLIJMEN J.C. et al.: Dehydroepiandrosterone replacement in women with adrenal insuffiency. N. Engl. J. Med., 1999, 341: 1013–1020.

  4. 4.

    ATKINSON L.E., CHANG Y.L. et al.: Long-term experience with testosterone replacement through scrotal skin. In: Nieschlag E., Behre H.M. eds. Testosterone, Action, Deficiency, Substitution. Berlin, Springer Verlag, 1998: 365–438.

  5. 5.

    BAULIEU E.E., THOMAS G., LEGRAIN S. et al.: Dehydroepiandrosterone (DHEA), DHEA sulphate, and aging: contribution of DHEAge study to sociobiomedical issue. Proc. Natl. Acad. Sci. U.S.A., 2000, 97: 4279–4284.

  6. 6.

    BEHRE H.M., KLIESCH S., LEIFKE E., LINK T.M., NIESCHLAG E.: Long term effect of testosterone therapy on bone density in hypogonadal men. J. Clin. Endocrinol. Metab., 1997, 82: 2386–2390.

  7. 7.

    CONTE-DEVOIX B.: Le diagnostic des déficits en hormone de croissance (GH) chez l’adulte. Med. Ther., 2002, 4: 33–35.

  8. 8.

    COOPER D.: Subclinical hypothyroidism. N. Engl. J. Med., 2001, 345: 260–265.

  9. 9.

    COSTA P.: Adénome prostatique, hormones et androgénothérapie. Andrologie, 2002, 12: 133–135.

  10. 10.

    DELHEZ M., HANSENNE M., LEGROS J.J.: Andropause and psychopathology: minor symptoms rater than pathological ones. Psychoneuroendocrinology, 2003, (sous presse).

  11. 11.

    DRINKA P.J., JOCHEN A.L., CUISINIER M., BLOOM R., RUDMAN I., RUDMAN D.: Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels. J. Am. Geriatr. Soc., 1995, 43: 899–901.

  12. 12.

    ENGLISH K.M., STEEDS R.P., JONES T.H., DIVER M.J., CHANNER K.S.: Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina. A randomized, double-blind, placebo-controlled study. Circulation, 2000, 102: 1906–1911.

  13. 13.

    FLAM T.: Traitement androgénique substitutif et cancer prostatique. Andrologie, 2002, 12: 136–137.

  14. 14.

    GARDNER F.H., NATHAN D.G., PIOMELLI S., CUMMINS J.F.: The erythrocytemic effects of androgens. Br. J. Haematol., 1968, 14: 611–615.

  15. 15.

    GARRY P.J., GOODWI J.S., HUNT W.C.: Iron status and anemia in the elderly. J. Am. Geriatr. Soc., 1983, 31: 389–399.

  16. 16.

    HAJJAR R.R., KAISER F.E., MORLEY J.E.: Outcomes of long-term testosterone replacement therapy in older hypogonadal males: a retrospective study. J. Clin. Endocrinol. Metab., 1997, 82: 3793–3796.

  17. 17.

    HEINEMANN L.A.J., ZIMMERMAN T., VERMEULEN A., THIEL C., HUMMEL W.: A new aging male symptoms rating scale. Aging Male, 1999, 2: 105–114.

  18. 18.

    HIBBERTS N.A., HOWELL A.E., RANDALL V.A.: Balding hair follicle dermal papilla cells contain higher levels of androgen receptors than those from non-balding scalp. J. Endocrinol., 1998, 156: 59–65.

  19. 19.

    JAMIN C.: HDL-cholestérol et stéroïdes sexuels: la fin d’un mythe? Lettre Gynécol., 2001, 258: 44–46.

  20. 20.

    JOCKENHOVEL F., VOGEL E., REINHARDT W., REINWEIN D.: Effects of various modes of androgen substitution therapy on erythropoiesis. Eur. J. Med. Res., 1997, 2: 293–298.

  21. 21.

    KAUFMAN J.M.: Androgens, bone metabolism and osteoporosis. In: Oddens B., Vermeulen A. eds. Androgens and the Aging male. Carnforth, UK, Parthenon Publishing, 1996: 39–63.

  22. 22.

    KENNEDY B.J., GILBERTSON A.S.: Increased erythropoiesis induced by androgenic-hormone therapy. N. Engl. J. Med., 1957, 256: 719.

  23. 23.

    KENNY A.M., PRESTWOOD K.M., RAISZ L.G.: Short-term effects of intramuscular and transdermal testosterone on bone turnover, prostate symptoms, cholesterol and hematocrit in men over age 70 with low testosterone levels. Endocr. Res., 2000, 26: 153–168.

  24. 24.

    KENNY A.M., PRESTWOOD K.M., GRUMAN C.A., MARCELLO K.M., RAISZ L.G.: Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J. Gerontol. A. Biol. Sci. Med. Sci., 2001, 56: M266–272.

  25. 25.

    KIM C.Y., BUVAT J., CARSON C.C. et al.: Endocrine and metabolic aspect including treatment. In: Jardin A., Wagner G., Khoury S., Giuliano F., Padma-Nathan H., Rosen, R. eds. Erectile dysfunction. 1st international consulation on erectile dysfunction, July 1–3, 1999, Paris. Plymouth, Health Publication Ltd, Plymbridge Distributors, 2000: 207–240.

  26. 26.

    KRAUSS D.J., TAUB H.A., LANTINGA L.J., DUNSKY M.H., KELLY C.M.: Risks of blood volume changes in hypogonadal men treated with testosterone enanthate for erectile impotence. J. Urol., 1991, 146: 1566–1570.

  27. 27.

    LEGROS J.J., DELHEZ M.: Détection de la déficience androgénique chez l’homme de plus de 50 ans: utilisation d’une version française du test ADAM. Med. Hyg., 2002, 60: 1490–1495.

  28. 28.

    LUBOSHITZKY R., AVIV A., HEFETZ A. et al.: Decreased pituitary-gonadal secretion in men with obstructive sleep apnea. J. Clin. Endocrinol. Metab., 2002, 87: 3394–3398.

  29. 29.

    MATSUMOTO A.M., SANDBLOM R.E., SCHOENE R.B. et al.: Testosterone replacement in hypogonadal men: effects on obstructive sleep apnea, respiratory drives, and sleep. Clin. Endocrinol., 1985, 22: 713–721.

  30. 30.

    MEIKLE AW. A permeation-enhanced non-scotal testosterone transdermal system for the treatment of male hypogonadism. In: Nieschlag E., Behre H.M. eds. Testosterone, Action, Deficiency, Substitution. Berlin, Springer Verlag, 1998: 390–422.

  31. 31.

    MORALES A., LUNENFELD B.: Androgen replacement therapy in aging male with secondary hypogonadism. Draft recommendations for endorment by ISSAM. Aging Male, 2001, 4: 151–162.

  32. 32.

    MORALES A, LUNENFELD B.: Standards, guidelines and recommandations of the International Society for the Study of the Aging Male (ISSAM). Investigation, treatment and monitoring of late-onset hypogonadism in males. Official Recommandations of ISSAM. Aging Male, 2002, 5: 74–86.

  33. 33.

    MORALES A. Androgen replacement therapy and prostate safety. Eur. Urol., 2002, 41: 113–120.

  34. 34.

    MORLEY J.E., CHARLTON E., PATRICK P. et al.: Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism, 2000, 49: 1239–1242.

  35. 35.

    MORLEY J.E., PERRY H.M. 3RD.: Androgen deficiency in aging men: role of testosterone replacement therapy. J. Lab. Clin. Med., 2000, 135: 370–378.

  36. 36.

    MORRIS F.K., LOY V.E. et al.: Hemoglobin concentration as determined by a methemoglobin method. Am. J. Clin. Pathol., 1956, 26: 1450–1455.

  37. 37.

    Report of the National Institute on Aging Advisory Panel on testosterone replacement in men. J. Clin. Endocrinol. Metab., 2001, 86: 4611–4614.

  38. 38.

    ROGER M., LAHLOU N.: Le déficit androgénique lié à l’âge: du diagnostic biologique au traitement substitutif. Andrologie, 2002, 12: 138–148.

  39. 39.

    ROSNER W.: Errors in the measurement of plasma free testosterone. J. Clin. Endocrinol. Metab., 1997, 82: 2014–2015.

  40. 40.

    SCHIAVI R.C., WHITE D., MANDELI J.: Pituitary-gonadal function during sleep in headline aging male. Psychoneuroendocrinology, 1992, 17: 599–609.

  41. 41.

    SHAHIDI N.T.: Androgens and erythropoiesis. N. Engl. J. Med., 1973, 289: 72–80.

  42. 42.

    SIH R., MORLEY J.E., KAISER F.E., PERRY H.M. 3RD, PATRICK P., ROSS C.: Testosterone replacement in older hypogonadal men: a 12 month randomized controlled study. J. Clin. Endocrinol. Metab., 1997, 82: 1661–1667.

  43. 43.

    SVETEC D.A., CANBY E.D., THOMPSON I.M., SABANEGH E.S. JR.: The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfonction. J. Urol., 1997, 158: 1775–1777.

  44. 44.

    TENOVER J.S.: Effects of testosterone supplementation in the aging male. J. Clin. Endocrinol. Metab., 1992, 75: 1092–1098.

  45. 45.

    TENOVER J.S.: Androgen administration to aging men. Endocrinol. Metab. Clin. North Am., 1994, 23: 877–892.

  46. 46.

    TREMBLAY R.R., MORALES A.: Canadian practice recommendations for screening, monitoring and treating men affected by andropause or partial androgen deficiency. Aging Male, 1998, 1: 213–218.

  47. 47.

    URBAN R.J., BODENBURG Y.H., GILKINSON C., FOWWORTH J., COGGAN A.R., WOLFE R.R.: Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am. J. Physiol., 1995, 269: E820-E826.

  48. 48.

    VERMEULEN A.: Commentary to the article-low levels of sex hormone-binding globulin and testosterone are associated with smaller, denser low density lipoproteins in normoglycemic men. J. Clin. Endocrinol. Metab., 1998, 83: 1822–1823.

  49. 49.

    VERMEULEN A., VERDONCK L., KAUFMAN J.L.: A critical evaluation of simple methods for the estimation of free testosterone in serum. J. Clin. Endocrinol. Metab., 1999, 84: 3666–3672.

  50. 50.

    WINTERS S.J., KELLEY D.E., GOODPASTER B.: The analog free testosterone assay: are the results in men clinically useful? Clin. Chem., 1998, 44: 2178–2182.

  51. 51.

    ZEITZER J., DANIELS J.E., DUFFY J.F. et al.: Do plasma melatonin concentrations decline with age? Am. J. Med., 1999, 107: 432–436.

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Hervé Lejeune.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cuzin, B., Guiliano, F., Jamin, C. et al. Diagnostic, traitement et surveillance de l’hypogonadisme de survenue tardive chez l’homme: Recommandations officielles de l’International Society for the Study of the Aging Male (ISSAM) et commentaires. Androl. 13, 331–347 (2003). https://doi.org/10.1007/BF03035201

Download citation

Mots-clés

  • homme
  • vieillissement
  • hypogonadisme
  • andropause
  • testostérone
  • traitement androgénique substitutif

Key words

  • man
  • aging
  • hypogonadism
  • andropause
  • testosterone
  • replacement androgen therapy